Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
    • 2.3.1.5 Epidemiology-based test volume estimation approach
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW
• 4.2 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
• 4.3 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030
• 4.4 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030
• 4.5 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030
• 4.6 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030
• 4.7 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
    • 5.2.1.2 Growing awareness about cervical cancer screening programs
    • 5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Growing awareness and adoption of HPV vaccination
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Regulatory guidelines for cervical cancer screening
    • 5.2.3.2 Innovative improvements in HPV tests
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Uncertain reimbursement scenario
    • 5.2.4.2 Stringent regulatory and legal requirements
    • 5.2.4.3 Operational barriers
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF HPV AND PAP TESTS
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Molecular diagnostics
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Cytology
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Immunodiagnostics
• 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 IMPORT DATA FOR HS CODE 3822
  • 5.12.2 EXPORT DATA FOR HS CODE 3822
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: UTILIZATION OF HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN THAILAND
  • 5.13.2 CASE STUDY 2: IMPLEMENTATION OF HUMAN PAPILLOMAVIRUS PRIMARY SCREENING OF CERVICAL CANCER IN BRITISH COLUMBIA
  • 5.13.3 CASE STUDY 3: COMPARATIVE EVALUATION OF HPV SELF-SAMPLING IN INDIA
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY FRAMEWORK
    • 5.14.1.1 NORTH AMERICA
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 Germany
      • 5.14.1.2.2 UK
      • 5.14.1.2.3 France
      • 5.14.1.2.4 Italy
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
      • 5.14.1.4.1 Brazil
      • 5.14.1.4.2 Mexico
    • 5.14.1.5 Middle East
    • 5.14.1.6 Africa
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF BUYERS
  • 5.15.2 BARGAINING POWER OF SUPPLIERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 IMPACT OF AI/GENERATIVE AI ON HPV TESTING AND PAP TEST MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI
  • 5.17.5 FUTURE OF AI IN HPV TESTING AND PAP TEST MARKET
• 5.18 IMPACT OF 2025 US TARIFFS ON HPV TESTING AND PAP TEST MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals
    • 5.18.5.2 Diagnostic laboratories
    • 5.18.5.3 Physicians' offices & clinics

6 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
• 6.3 INSTRUMENTS
  • 6.3.1 INCREASING ADOPTION OF AUTOMATED DIAGNOSTIC SYSTEMS TO DRIVE GROWTH
• 6.4 SERVICES
  • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND

7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 HPV TESTING
  • 7.2.1 PRIMARY HPV TESTING
    • 7.2.1.1 Test sensitivity and accuracy to drive growth
  • 7.2.2 FOLLOW-UP HPV TESTING
    • 7.2.2.1 Irregular Pap test results to drive adoption
  • 7.2.3 CO-TESTING
    • 7.2.3.1 Co-testing to drive rapid detection results for cervical cancer
• 7.3 PAP TESTS
  • 7.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET

8 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 MOLECULAR DIAGNOSTICS
  • 8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN HPV DETECTION TO DRIVE MARKET GROWTH
• 8.3 IMMUNODIAGNOSTICS
  • 8.3.1 COST BENEFITS OF IMMUNOASSAYS TO BOOST DEMAND
• 8.4 CYTOLOGY
  • 8.4.1 AUTOMATION AND DIGITAL IMAGING TO DRIVE ADOPTION

9 HPV TESTING AND PAP TEST MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CERVICAL CANCER SCREENING
  • 9.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
• 9.3 VAGINAL CANCER SCREENING
  • 9.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET

10 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
• 10.3 DIAGNOSTIC LABORATORIES
  • 10.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
• 10.4 PHYSICIANS' OFFICES & CLINICS
  • 10.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH

11 HPV TESTING AND PAP TEST MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising government initiatives for cervical cancer testing to expedite growth
  • 11.2.3 CANADA
    • 11.2.3.1 Growing awareness of cervical cancer screening to support growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Established healthcare infrastructure and rising healthcare spending to promote growth
  • 11.3.3 UK
    • 11.3.3.1 Rising focus on research projects for specific cancers to contribute to growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High incidence of cervical cancer and associated investments in genomics to stimulate growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to boost market
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing research on cancer diagnostics to accelerate growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Growing public access to modern healthcare to propel market
  • 11.4.3 JAPAN
    • 11.4.3.1 Rising demand for technologically advanced cervical cancer screening tests to facilitate growth
  • 11.4.4 INDIA
    • 11.4.4.1 Expanding healthcare access and high cervical cancer burden to drive market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Universal healthcare access to speed up growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Improved access to healthcare to sustain growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 SAUDI ARABIA
    • 11.6.2.1 Rising government healthcare expenditure to augment growth
  • 11.6.3 UAE
    • 11.6.3.1 Increasing emphasis on healthy lifestyles and quality of life to encourage growth
  • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.5.1 COMPANY VALUATION
  • 12.5.2 FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product & service footprint
    • 12.7.5.4 Test type footprint
    • 12.7.5.5 Technology footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 HOLOGIC, INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Right to win
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses and competitive threats
  • 13.1.2 BECTON, DICKINSON AND COMPANY (BD)
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 QIAGEN
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 DANAHER CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses and competitive threats
  • 13.1.6 ABBOTT
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 SEEGENE INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches and approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 SD BIOSENSOR, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 SANSURE BIOTECH INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 ACON LABORATORIES, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MOLBIO DIAGNOSTICS LIMITED
  • 13.2.2 AB ANALITICA S.R.L.
  • 13.2.3 CERTEST BIOTEC
  • 13.2.4 ATILA BIOSYSTEMS
  • 13.2.5 TELLGEN CORPORATION
  • 13.2.6 DAAN GENE CO., LTD.
  • 13.2.7 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
  • 13.2.8 ANATOLIA GENEWORKS
  • 13.2.9 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
  • 13.2.10 XIAMEN ZEESAN BIOTECH CO., LTD.
  • 13.2.11 ADVANCED MOLECULAR DIAGNOSTICS (AMD)
  • 13.2.12 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
  • 13.2.13 SACACE BIOTECHNOLOGIES SRL
  • 13.2.14 JIANGSU MOLE BIOSCIENCE CO., LTD.
  • 13.2.15 HANGZHOU ALLTEST BIOTECH CO., LTD.
  • 13.2.16 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.
  • 13.2.17 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 HPV TESTING AND PAP TEST MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 HPV TESTING AND PAP TEST MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 3 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT ANALYSIS
• TABLE 4 ESTIMATED NUMBER OF NEW CASES OF CERVICAL CANCER, BY REGION, 2022 VS. 2030
• TABLE 5 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, 2023-2025 (USD)
• TABLE 6 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, BY REGION (USD)
• TABLE 7 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY KEY PLAYER, 2023-2025 (USD)
• TABLE 8 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY REGION, 2023-2025 (USD)
• TABLE 9 HPV TESTING AND PAP TEST MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 10 HPV TESTING AND PAP TEST MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
• TABLE 11 HPV TESTING AND PAP TEST MARKET: LIST OF MAJOR PATENTS, 2023-2025
• TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE
• TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
• TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 21 HPV TESTING AND PAP TEST MARKET: IMPACT OF PORTER'S FIVE FORCES
• TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
• TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
• TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US
• TABLE 25 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 26 KEY CONSUMABLES AVAILABLE IN MARKET
• TABLE 27 HPV TESTING AND PAP TEST CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 KEY INSTRUMENTS AVAILABLE IN MARKET
• TABLE 29 HPV TESTING AND PAP TEST INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 30 HPV TESTING AND PAP TEST SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 31 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 32 KEY HPV TESTING PRODUCTS AVAILABLE IN MARKET
• TABLE 33 HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 34 HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 35 NORTH AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 EUROPE: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 ASIA PACIFIC: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 LATIN AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 39 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 PRIMARY HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 41 NORTH AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 42 EUROPE: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 ASIA PACIFIC: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 44 LATIN AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 MIDDLE EAST & AFRICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 46 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 47 NORTH AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 48 EUROPE: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 49 ASIA PACIFIC: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 50 LATIN AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 MIDDLE EAST & AFRICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 CO-TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 53 NORTH AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 EUROPE: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 ASIA PACIFIC: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 LATIN AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 57 MIDDLE EAST & AFRICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 KEY PAP TESTS AVAILABLE IN MARKET
• TABLE 59 PAP TESTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 60 NORTH AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 EUROPE: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 62 ASIA PACIFIC: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 LATIN AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 MIDDLE EAST & AFRICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 66 KEY MOLECULAR DIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET
• TABLE 67 HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 68 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 70 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 KEY IMMUNODIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET
• TABLE 74 HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 75 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 77 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 81 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 82 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 87 KEY HPV TESTING AND PAP TESTS FOR CERVICAL CANCER SCREENING AVAILABLE IN MARKET
• TABLE 88 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 89 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 92 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 KEY HPV TESTING AND PAP TESTS FOR VAGINAL CANCER SCREENING AVAILABLE IN MARKET
• TABLE 95 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 96 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 97 EUROPE: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 99 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 102 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 103 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 104 EUROPE: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 109 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 110 EUROPE: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 115 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 116 EUROPE: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 117 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 118 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 PROJECTED CERVICAL CANCER CASES, BY COUNTRY, 2022 VS. 2030
• TABLE 121 HPV TESTING AND PAP TEST MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 122 TOTAL NUMBER OF HPV TESTS CONDUCTED, BY REGION, 2023-2030 (MILLION UNIT)
• TABLE 123 TOTAL NUMBER OF PAP TESTS CONDUCTED, BY REGION, 2023-2030 (MILLION UNIT)
• TABLE 124 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 125 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 126 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 127 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 128 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 129 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 130 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 131 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 132 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 133 US: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 134 US: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 135 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 136 US: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 137 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 138 CANADA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 139 CANADA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 140 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 141 CANADA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 142 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 143 EUROPE: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 144 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 145 EUROPE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 146 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 147 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 148 EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 149 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 150 GERMANY: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 151 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 152 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 153 GERMANY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 154 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 155 UK: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 156 UK: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 157 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 158 UK: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 159 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 160 FRANCE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 161 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 162 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 163 FRANCE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 164 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 165 ITALY: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 166 ITALY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 167 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 168 ITALY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 169 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 170 SPAIN: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 171 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 172 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 173 SPAIN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 174 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 175 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 176 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 177 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 178 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 179 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
• TABLE 180 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 181 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 183 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 184 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 185 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 186 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 187 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 188 CHINA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 189 CHINA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 190 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 191 CHINA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 192 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 193 JAPAN: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 194 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 195 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 196 JAPAN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 197 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 198 INDIA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 199 INDIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 200 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 201 INDIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 202 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 203 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 204 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 205 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 206 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 207 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 208 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 210 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 211 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 212 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 213 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 214 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 215 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 216 BRAZIL: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 217 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 218 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 219 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 220 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 221 MEXICO: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 222 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 223 MEXICO: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 224 MEXICO: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 225 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 226 REST OF LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 227 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 228 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 229 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 230 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
• TABLE 231 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 232 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 233 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 234 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 235 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 236 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 237 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 238 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 239 SAUDI ARABIA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 240 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 241 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 242 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 243 UAE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 244 UAE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 245 UAE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 246 UAE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 247 UAE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 248 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
• TABLE 249 REST OF MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 250 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 251 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 252 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
• TABLE 253 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, JANUARY 2022-SEPTEMBER 2025
• TABLE 254 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION
• TABLE 255 HPV TESTING AND PAP TEST MARKET: REGION FOOTPRINT
• TABLE 256 HPV TESTING AND PAP TEST MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 257 HPV TESTING AND PAP TEST MARKET: TEST TYPE FOOTPRINT
• TABLE 258 HPV TESTING AND PAP TEST MARKET: TECHNOLOGY FOOTPRINT
• TABLE 259 HPV TESTING AND PAP TEST MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 260 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND TEST TYPE
• TABLE 261 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION
• TABLE 262 HPV TESTING AND PAP TEST MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 263 HPV TESTING AND PAP TEST MARKET: DEALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 264 HPV TESTING AND PAP TEST MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
• TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 266 HOLOGIC, INC.: PRODUCTS OFFERED
• TABLE 267 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
• TABLE 268 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
• TABLE 269 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 270 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 271 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
• TABLE 272 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 273 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 274 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 275 QIAGEN: COMPANY OVERVIEW
• TABLE 276 QIAGEN: PRODUCTS OFFERED
• TABLE 277 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
• TABLE 278 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 279 DANAHER CORPORATION: PRODUCTS OFFERED
• TABLE 280 ABBOTT: COMPANY OVERVIEW
• TABLE 281 ABBOTT: PRODUCTS OFFERED
• TABLE 282 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 283 ABBOTT: DEALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 284 SEEGENE INC.: COMPANY OVERVIEW
• TABLE 285 SEEGENE INC.: PRODUCTS OFFERED
• TABLE 286 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 287 SEEGENE INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 288 SD BIOSENSOR, INC.: COMPANY OVERVIEW
• TABLE 289 SD BIOSENSOR, INC.: PRODUCTS OFFERED
• TABLE 290 SANSURE BIOTECH INC.: COMPANY OVERVIEW
• TABLE 291 SANSURE BIOTECH INC.: PRODUCTS OFFERED
• TABLE 292 SANSURE BIOTECH INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 293 SANSURE BIOTECH INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
• TABLE 294 ACON LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 295 ACON LABORATORIES, INC.: PRODUCTS OFFERED
• TABLE 296 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
• TABLE 297 AB ANALITICA S.R.L.: COMPANY OVERVIEW
• TABLE 298 CERTEST BIOTEC: COMPANY OVERVIEW
• TABLE 299 ATILA BIOSYSTEMS: COMPANY OVERVIEW
• TABLE 300 TELLGEN CORPORATION: COMPANY OVERVIEW
• TABLE 301 DAAN GENE CO., LTD.: COMPANY OVERVIEW
• TABLE 302 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.: COMPANY OVERVIEW
• TABLE 303 ANATOLIA GENEWORKS: COMPANY OVERVIEW
• TABLE 304 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.: COMPANY OVERVIEW
• TABLE 305 XIAMEN ZEESAN BIOTECH CO., LTD.: COMPANY OVERVIEW
• TABLE 306 ADVANCED MOLECULAR DIAGNOSTICS (AMD): COMPANY OVERVIEW
• TABLE 307 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: COMPANY OVERVIEW
• TABLE 308 SACACE BIOTECHNOLOGIES SRL: COMPANY OVERVIEW
• TABLE 309 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW
• TABLE 310 HANGZHOU ALLTEST BIOTECH CO., LTD.: COMPANY OVERVIEW
• TABLE 311 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
• TABLE 312 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION AND REGIONAL SCOPE
• FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN METHODOLOGY
• FIGURE 3 PRIMARY SOURCES
• FIGURE 4 KEY INDUSTRY INSIGHTS
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 9 EPIDEMIOLOGY-BASED TEST VOLUME ESTIMATION APPROACH
• FIGURE 10 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH
• FIGURE 11 DATA TRIANGULATION METHODOLOGY
• FIGURE 12 HPV TESTING AND PAP TEST MARKET: RESEARCH ASSUMPTIONS
• FIGURE 13 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030(USD MILLION)
• FIGURE 16 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030 (USD MILLION)
• FIGURE 18 HPV TESTING AND PAP TEST MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• FIGURE 19 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET
• FIGURE 20 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 HPV TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 22 MOLECULAR DIAGNOSTICS SEGMENT TO SHOWCASE LARGEST MARKET SHARE DURING FORECAST PERIOD
• FIGURE 23 CERVICAL CANCER SCREENING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
• FIGURE 24 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030
• FIGURE 25 NORTH AMERICAN MARKET TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
• FIGURE 26 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN HPV TESTING AND PAP TEST MARKET
• FIGURE 28 HPV TESTING AND PAP TEST MARKET: VALUE CHAIN ANALYSIS
• FIGURE 29 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 30 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM ANALYSIS
• FIGURE 31 HPV TESTING AND PAP TEST MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2025
• FIGURE 32 HPV TESTING AND PAP TEST MARKET: PATENT ANALYSIS, JANUARY 2015-DECEMBER 2024
• FIGURE 33 HPV TESTING AND PAP TEST MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
• FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
• FIGURE 36 MARKET POTENTIAL OF AI IN HPV TESTING AND PAP TEST MARKET
• FIGURE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT
• FIGURE 38 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT
• FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2022-2024
• FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2024
• FIGURE 41 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 42 EV/EBITDA OF KEY VENDORS
• FIGURE 43 HPV TESTING AND PAP TEST MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 44 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 45 HPV TESTING AND PAP TEST MARKET: COMPANY FOOTPRINT
• FIGURE 46 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT
• FIGURE 48 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
• FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• FIGURE 50 QIAGEN: COMPANY SNAPSHOT
• FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT
• FIGURE 52 ABBOTT: COMPANY SNAPSHOT
• FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT
• FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT